Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.
Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB/c mice bearing MT-901 breast...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3714270?pdf=render |
| _version_ | 1828390798978187264 |
|---|---|
| author | Paul Toomey Krithika Kodumudi Amy Weber Lisa Kuhn Ellen Moore Amod A Sarnaik Shari Pilon-Thomas |
| author_facet | Paul Toomey Krithika Kodumudi Amy Weber Lisa Kuhn Ellen Moore Amod A Sarnaik Shari Pilon-Thomas |
| author_sort | Paul Toomey |
| collection | DOAJ |
| description | Intralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10. Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma production compared to splenocytes from PBS-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T cells isolated after PV-10 treatment was observed. Transfer of T cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in mice bearing B16 melanoma. These studies establish that IL PV-10 therapy induces tumor-specific T cell-mediated immunity in multiple histologic subtypes and support the concept of combining IL PV10 with immunotherapy for advanced malignancies. |
| first_indexed | 2024-12-10T06:51:13Z |
| format | Article |
| id | doaj.art-3f013f3b0e4f48779f3c4bfa61102fb4 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-10T06:51:13Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-3f013f3b0e4f48779f3c4bfa61102fb42022-12-22T01:58:32ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e6856110.1371/journal.pone.0068561Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer.Paul ToomeyKrithika KodumudiAmy WeberLisa KuhnEllen MooreAmod A SarnaikShari Pilon-ThomasIntralesional (IL) injection of PV-10 has shown to induce regression of both injected and non-injected lesions in patients with melanoma. To determine an underlying immune mechanism, the murine B16 melanoma model and the MT-901 breast cancer model were utilized. In BALB/c mice bearing MT-901 breast cancer, injection of PV-10 led to regression of injected and untreated contralateral subcutaneous lesions. In a murine model of melanoma, B16 cells were injected into C57BL/6 mice to establish one subcutaneous tumor and multiple lung lesions. Treatment of the subcutaneous lesion with a single injection of IL PV-10 led to regression of the injected lesion as well as the distant B16 melanoma lung metastases. Anti-tumor immune responses were measured in splenocytes collected from mice treated with IL PBS or PV-10. Splenocytes isolated from tumor bearing mice treated with IL PV-10 demonstrated enhanced tumor-specific IFN-gamma production compared to splenocytes from PBS-treated mice in both models. In addition, a significant increase in lysis of B16 cells by T cells isolated after PV-10 treatment was observed. Transfer of T cells isolated from tumor-bearing mice treated with IL PV-10 led to tumor regression in mice bearing B16 melanoma. These studies establish that IL PV-10 therapy induces tumor-specific T cell-mediated immunity in multiple histologic subtypes and support the concept of combining IL PV10 with immunotherapy for advanced malignancies.http://europepmc.org/articles/PMC3714270?pdf=render |
| spellingShingle | Paul Toomey Krithika Kodumudi Amy Weber Lisa Kuhn Ellen Moore Amod A Sarnaik Shari Pilon-Thomas Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. PLoS ONE |
| title | Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. |
| title_full | Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. |
| title_fullStr | Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. |
| title_full_unstemmed | Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. |
| title_short | Intralesional injection of rose bengal induces a systemic tumor-specific immune response in murine models of melanoma and breast cancer. |
| title_sort | intralesional injection of rose bengal induces a systemic tumor specific immune response in murine models of melanoma and breast cancer |
| url | http://europepmc.org/articles/PMC3714270?pdf=render |
| work_keys_str_mv | AT paultoomey intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer AT krithikakodumudi intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer AT amyweber intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer AT lisakuhn intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer AT ellenmoore intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer AT amodasarnaik intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer AT sharipilonthomas intralesionalinjectionofrosebengalinducesasystemictumorspecificimmuneresponseinmurinemodelsofmelanomaandbreastcancer |